Cure Rates for Aplastic Anemia
Aplastic anemia is highly curable with appropriate treatment, achieving long-term survival rates of 80-90% in most patients, with cure rates reaching up to 90% in young patients receiving matched sibling donor transplantation 1.
Age-Dependent Cure Rates
The curability of aplastic anemia varies significantly by age and treatment modality:
Young Patients (<40 years)
- Matched sibling donor hematopoietic cell transplantation (HCT): 80-90% disease-free survival, with children under 10 years having especially superior outcomes 1
- Young adults (20-40 years): 80-90% probability of disease-free survival after matched sibling HCT 1
- Children with matched sibling donors: 79% cure rate with allogeneic bone marrow transplantation 2
Older Patients (>40 years)
- Overall long-term survival: >80-90% with modern supportive care improvements 1
- For this age group, immunosuppressive therapy (IST) is preferred over HCT due to higher transplant-related risks 1
Treatment-Specific Outcomes
Hematopoietic Cell Transplantation
- Matched sibling donors: Up to 90% cure rate 3, with 80% cure rates in recent studies 4
- Unrelated donors: 70% cure rate 4, with 37% survival in CD34+ enriched, partially T-cell depleted transplants 3
- Cord blood: Emerging as a newer stem cell source 3
Immunosuppressive Therapy
- Overall response rate: 70-80% hematological response 5
- Complete remission: 25-55% depending on the study 2, 6
- 5-year survival in responders: 80-90% 3
- Relapse rate: Approximately 10% 3
Important Caveats
A critical pitfall is that "cure" differs between treatment modalities: HCT offers true cure with disease-free survival, while IST achieves remission but carries risks of relapse (10%) and clonal evolution to paroxysmal nocturnal hemoglobinuria or myelodysplastic syndrome 5.
Recent improvements in supportive care have dramatically improved outcomes: In recent decades, treatment-related mortality has decreased considerably with either HCT or IST, resulting in >80-90% long-term survivors 1.
Without treatment, outcomes are dismal: Supportive care alone results in 75% mortality with very short survival times 2, emphasizing the importance of definitive therapy.
Treatment Selection Algorithm
The 2026 ASH guidelines provide clear direction 1:
- Age <40 years with matched sibling donor available: HCT is first-line treatment
- Age >40 years: IST is preferred over HCT, even with matched sibling donor available
- No matched sibling donor: IST with consideration of unrelated donor HCT as second-line after IST failure
- Modern IST regimens: Include eltrombopag addition to improve outcomes 1
The overall message is optimistic: with appropriate treatment selection based on age and donor availability, the vast majority of aplastic anemia patients can expect long-term survival or cure.